François Laliberté/LinkedIn
Aug 6, 2025, 12:52
RPTH Journal: Rivaroxaban vs Warfarin in PE with RV Dysfunction
RPTH Journal shared a new study on LinkedIn:
”Do clinical outcomes differ between patients treated with rivaroxaban vs warfarin for PE/RVD?
Rivaroxaban was more effective than warfarin without a significant increase in safety.”
Read the full article here.
Article: Effectiveness and safety of rivaroxaban vs warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study
Authors: François Laliberté, Behnood Bikdeli, Veronica Ashton, Guillaume Germain, Julien Boudreau, Manasvi Sundar, Sean D. MacKnight, Brahim Bookhart, Dereck Wentworth, Shawn Murphy, Yichuan G. Hsieh, Gregory Piazza
Find the latest scientific advances featured in Hemostasis Today.
Behnood Bikdeli
Brahim Bookhart
Dereck Wentworth
François Laliberté
Gregory Piazza
Guillaume Germain
Health
Hematology
Hemostasis Today
Julien Boudreau
Manasvi Sundar
Medicine
PE
Pulmonary embolism
right ventricular dysfunction
Rivaroxaban
Rivaroxaban vs Warfarin
RPTH Journal
RVD
Sean D. MacKnight
Shawn Murphy
Veronica Ashton
Warfarin
Yichuan G. Hsieh
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
-
Jul 7, 2026, 20:59William Aird: An Unlucky Turn Into the Renal Artery
-
Jul 7, 2026, 20:58Chokri Ben Lamine: The Two-Hit Model of TRALI
-
Jul 7, 2026, 20:57New Issue of Blood Out Now – Blood Journals Portfolio
-
Jul 7, 2026, 20:56Priyadarshini Ramakrishnan: Schistocytes – The Most “Misleading Heroes” in a Peripheral Smear
-
Jul 7, 2026, 20:55Natasa Blagojevic-Stokic: Exploring the Role of ATP and Calcium Homeostasis in Autism
-
Jul 7, 2026, 17:49Alan Nurden: Safer Antithrombotic Therapy Through GPVI
-
Jul 7, 2026, 17:29Anticoagulation Reversal in 2026: Are We Winning the Bleeding Battle? – Francisco Chacón-Lozsán
-
Jul 7, 2026, 17:25Jim Hoffman: Targeting NETosis to Restore Immune Homeostasis